Trust Company of Vermont’s Krystal Biotech KRYS Stock Holding History

Trust Company of Vermont’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.43K	Buy	+20	New	+$5.98K	﹤0.01%	949
2025 Q4	$4.93K	Hold	20	–	–	﹤0.01%	942
2025 Q3	$3.53K	Hold	20	–	–	﹤0.01%	965
2025 Q2	$2.75K	Hold	20	–	–	﹤0.01%	980
2025 Q1	$3.61K	Hold	20	–	–	﹤0.01%	890
2024 Q4	$3.13K	Buy	+20	New	+$3.55K	﹤0.01%	913

Other funds holding KRYS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Trust Company of Vermont's KRYS Position: Q2 2026 in Review

Trust Company of Vermont opened a new position in Krystal Biotech (KRYS) in Q2 2026: 20 shares worth $7.43K. The stake represents ﹤0.01% of the portfolio and ranks #949 among its holdings. This is a return to the name: Trust Company of Vermont previously reported a position in KRYS as recently as Q4 2025.

Trust Company of Vermont first reported a position in KRYS in Q4 2024 and has held it in 6 quarters since. 190 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Trust Company of Vermont held 20 shares of Krystal Biotech worth $7.43K as of Q2 2026.
Krystal Biotech was a new Trust Company of Vermont position in Q2 2026.
Krystal Biotech made up ﹤0.01% of Trust Company of Vermont's portfolio in Q2 2026, its #949 holding.
Trust Company of Vermont first reported a position in Krystal Biotech in Q4 2024 and has held it in 6 quarters since.
190 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Trust Company of Vermont's 13F filing for Q2 2026, filed 7 Aug 2026.